{
    "clinical_study": {
        "@rank": "34974", 
        "arm_group": [
            {
                "arm_group_label": "BAY94-8862 (1.25mg)", 
                "arm_group_type": "Experimental", 
                "description": "single dose BAY94-8862 IR tablet 1.25mg"
            }, 
            {
                "arm_group_label": "BAY94-8862 (2.5mg)", 
                "arm_group_type": "Experimental", 
                "description": "single dose BAY94-8862 IR tablet 2.5mg"
            }, 
            {
                "arm_group_label": "BAY94-8862 (5mg)", 
                "arm_group_type": "Experimental", 
                "description": "single dose BAY94-8862 IR tablet 5mg"
            }, 
            {
                "arm_group_label": "BAY94-8862 (7.5mg)", 
                "arm_group_type": "Experimental", 
                "description": "single dose BAY94-8862 IR tablet 7.5mg"
            }, 
            {
                "arm_group_label": "BAY94-8862 (10mg)", 
                "arm_group_type": "Experimental", 
                "description": "single dose BAY94-8862 IR tablet 10mg"
            }
        ], 
        "brief_summary": {
            "textblock": "This study should estimate the dose proportionality of BAY94-8862 IR tablets."
        }, 
        "brief_title": "Dose Proportionality Study With BAY94-8862 IR (Immediate Release) Tablets", 
        "completion_date": {
            "#text": "November 2012", 
            "@type": "Actual"
        }, 
        "condition": "Heart Failure", 
        "condition_browse": {
            "mesh_term": "Heart Failure"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy male subject\n\n          -  Age: 18 to 46 years (inclusive) at the first screening examination\n\n          -  Ethnicity: White\n\n          -  Body mass index (BMI): >= 18 and <= 29.9 kg / m\u00b2\n\n        Exclusion Criteria:\n\n          -  Clinically relevant findings in the ECG (electrocardiogram) such as a second- or\n             third-degree AV block, prolongation of the QRS complex over 120 msec\n\n          -  Systolic blood pressure below 100 or above 140 mmHg\n\n          -  Diastolic blood pressure below 50 or above 90 mmHg\n\n          -  Heart rate below 50 or above 95 beats/ min\n\n          -  Positive results for hepatitis B virus surface antigen (HBsAg), hepatitis C virus\n             antibodies (anti-HCV), human immune deficiency virus antibodies (anti-HIV 1+2)\n\n          -  Participation in another clinical study during the preceding 3 months (Last Treatment\n             from previous study to First Treatment of new study)"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "46 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "25", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "September 14, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01687920", 
            "org_study_id": "15481", 
            "secondary_id": "2012-003055-10"
        }, 
        "intervention": [
            {
                "arm_group_label": "BAY94-8862 (1.25mg)", 
                "intervention_name": "BAY94-8862 (1.25mg)", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "BAY94-8862 (2.5mg)", 
                "intervention_name": "BAY94-8862 (2.5mg)", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "BAY94-8862 (5mg)", 
                "intervention_name": "BAY94-8862 (5mg)", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "BAY94-8862 (7.5mg)", 
                "intervention_name": "BAY94-8862 (7.5mg)", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "BAY94-8862 (10mg)", 
                "intervention_name": "BAY94-8862 (10mg)", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": "Cardiac disorders", 
        "lastchanged_date": "January 8, 2014", 
        "link": [
            {
                "description": "Click here and search for drug information provided by the FDA.", 
                "url": "http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm"
            }, 
            {
                "description": "Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.", 
                "url": "http://www.fda.gov/medwatch/safety.htm"
            }, 
            {
                "description": "Click here to find results for studies related to Bayer Healthcare products.", 
                "url": "http://healthcare.bayer.com/scripts/pages/en/research_development/clinical_trials/trial_finder/index.php"
            }
        ], 
        "location": {
            "facility": {
                "address": {
                    "city": "M\u00f6nchengladbach", 
                    "country": "Germany", 
                    "state": "Nordrhein-Westfalen", 
                    "zip": "41061"
                }
            }
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "5", 
        "official_title": "Single Center, Randomized, Open-label, 5-fold Crossover Study in Healthy Male Subjects to Investigate the Pharmacokinetic Dose Proportionality of BAY94-8862 Given as 5 Different Single Oral IR Tablet Doses (1.25, 2.5, 5.0, 7.5 and 10 mg)", 
        "overall_official": {
            "affiliation": "Bayer", 
            "last_name": "Bayer Study Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Germany: Federal Institute for Drugs and Medical Devices", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "November 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Dose proportionality of BAY94-8862 exposure in plasma when given as 1.25, 2.5, 5.0, 7.5 and 10 mg IR tablets", 
            "safety_issue": "No", 
            "time_frame": "0, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 15, 24, 28 & 48 h"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01687920"
        }, 
        "responsible_party": {
            "name_title": "Head of Clinical Sciences", 
            "organization": "Bayer Healthcare AG"
        }, 
        "secondary_outcome": {
            "measure": "Number of participants with adverse events as a measure of safety and tolerability of BAY94-8862", 
            "safety_issue": "Yes", 
            "time_frame": "Up to 48 h"
        }, 
        "source": "Bayer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Bayer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}